Elizabeth L. Hougen, Executive Vice President, Finance & CFO of Ionis Pharmaceuticals Inc. (NASDAQ:IONS), recently executed several transactions involving the company's common stock. According to a recent SEC filing, Hougen sold 8,870 shares on January 16 at a weighted average price of $32.806 per share, amounting to a total of $290,989. This sale was made to cover tax withholding obligations as part of the 2011 Equity Incentive Plan.
Additionally, Hougen acquired 23,887 shares on January 15 through the vesting and release of shares from Restricted Stock Unit awards. These transactions reflect ongoing management activities under Ionis Pharmaceuticals' equity incentive programs. The company maintains a strong liquidity position with a current ratio of 8.91, though it reported a loss per share of $2.46 over the last twelve months. InvestingPro subscribers can access 8 additional key insights and a comprehensive Pro Research Report about Ionis Pharmaceuticals, helping investors make more informed decisions.
In other recent news, Ionis Pharmaceuticals has maintained its positive ratings from Piper Sandler and Needham following the FDA's approval of its drug TRYNGOLZA, or olezarsen, for the treatment of familial chylomicronemia syndrome (FCS). The drug, priced at $595,000 per year, is expected to generate $37 million in U.S. FCS revenue for the fiscal year 2025, according to Piper Sandler. Ionis plans to transition patients from Open-Label Extension (OLE) and Expanded Access Program (EAP) to the commercial drug during the first half of 2025.
Additionally, the company is awaiting results from pivotal studies for the drug's use in severe hypertriglyceridemia (sHTG), expected in the second half of 2025. Analysts from Needham have indicated the possibility of a price reduction if the drug also receives approval for this broader indication.
In its third quarter 2024 financial results, Ionis emphasized its non-GAAP financials, reflecting the company's confidence in its operational management and long-term prospects. These recent developments underscore Ionis Pharmaceuticals' ongoing strides in the pharmaceutical industry, with the FDA approval marking a significant milestone in the company's transition into a new phase of commercial drug distribution.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.